ABSTRACT
@#AIM: To investigate the effect of comprehensive treatment of ocular alkali burn in different periods.<p>METHOD: A retrospective analysis was performed on 124 cases(166 eyes)of ocular alkali burns admitted to our hospital from January 2019 to December 12. According to the severity of the disease, a number of comprehensive measures were taken to treat the ocular alkali burn with drugs and surgery respectively. The patients were followed up for 6-12mo to observe the healing of ocular alkali burn and the final outcome of disease.<p>RESULTS: After treatment, the symptoms of all patients were relieved, the corneal conjunctiva healed, and no infection occurred. The average hospitalization time was 13d, totally 118 eyes were cured(71.1%), 43 eyes were improved(25.9%), 5 eyes were ineffective(3.0%). There was no complication in degree I and degree II of ocular alkali burn patients, degree III was better than degree IV, and the complication rate in degree III was lower than that in degree IV.<p>CONCLUSION: According to the corneal conjunctiva and eyelid injury evaluation of ocular alkali burn degree, choose appropriate time to take corresponding treatment measures, and give systemic and local drug treatment. Combined with ocular surface irrigation, anterior chamber puncture, amniotic membrane transplantation, conjunctival flap covering, corneal transplantation, limbal stem cell transplantation and other comprehensive treatment methods can obtain good clinical effect.
ABSTRACT
Objective The inhibitory effects of avastin on new blood vessels in nonproliferation diabetic retinopathy, age-related macular degeneration and neovascular glaucoma have been demonstrated. But only seldom report of avastin on corneal neovascularization(CNV) was seen. Present study was to evaluate the effect of topical bevacizumab (avastin) on experimental corneal neovascularization in mice. Methods Thirty eyes of 30 Balb/c mice were chemically cauterized by applying a 2 mm-diameter filter paper soaked 1 mol/L NaOH solution at the central cornea for 40 s. All animals were randomly assigned to five groups, including 1 mg/mL, 3 mg/mL and 5 mg/mL bevacizumab eye drops group respectively, 1 mg/mL dexamethasone sodium phosphate eye drops group (positive control) and normal saline solution group (negative control) . The drug was topically utilized twice per day. CNV was examined under the slim lamp on the 3rd, 7th and 14th day after alkali burn. Animals were killed on the 14th day after alkali burn. Area of CNV was calculated in terms of pixels on digital photographs. The use of animals followed the Regulations for the Administration of Affair Concerning Experimental Animals by State Science and Technology Commission. Results No significant difference was found in the grade of corneal injury among five groups (F = 0. 201, P = 0. 935). The area of neovascularization at the cornea surface was (37.11 ±3.17)% in 1 mg/mL bevacizumab group, (29.75 ±3.56)% in 3 mg/mL bevacizumab group, (18. 76 ± 2. 55) % in 5 mg/mL bevacizumab group, (20. 91 ± 2. 75) % in dexamethasone group and (41. 65 ±2. 11)% in normal saline group, showing a significant difference among groups(F = 71. 687, P =0. 000) with the further comparative decline in 5 mg/mL bevacizumab group compared with other groups (P ＜ 0. 01) . Conclusion The topical use of bevacizumab (avastin) inhibits alkali burn-induced CNV in mice.